By Ben Glickman

Taysha Gene Therapies will discontinue development of its TSHA-120 program to treat giant axonal neuropathy after receiving feedback from the U.S. Food and Drug Administration.

The Dallas-based gene-therapy developer said that it had received Type C meeting feedback from the FDA. Chief Executive Sean Nolan said that the feedback pointed out "challenges related to the feasibility of the study designs" to support approval by the FDA.

The company will pursue external strategic options for TSHA-120, which is meant to extend Taysha's cash runway into the fourth quarter of 2025.

Taysha said that Astellas Gene Therapy had decided not to exercise its exclusive license option under a prior agreement between the two companies.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

September 19, 2023 16:37 ET (20:37 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Taysha Gene Therapies (NASDAQ:TSHA)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Taysha Gene Therapies
Grafico Azioni Taysha Gene Therapies (NASDAQ:TSHA)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Taysha Gene Therapies